Anticancer therapy in patients with porphyrias: evidence today.

Abstract : BACKGROUND: Porphyrias are rare diseases, and for these patients every administration of drugs may induce an acute attack of porphyria. The list of safe compounds allowed in these patients is available for clinicians from specific websites cited in the text. OBJECTIVES: However, data concerning anticancer therapy in patients with such diseases remain poor. Therefore any publications can help clinicians to deal with this very specific group of patients. METHODS: In our institution, three patients received docetaxel and hematologic growth factors (erythropoietin and GCSF) without unexpected toxicities. Aromatase inhibitors (anstrozole and letrozole) were also given in one patient without any related problem. CONCLUSION: The present observation adds some useful data for the possible treatment of cancer in patients with porphyria.
Type de document :
Article dans une revue
Expert Opinion on Drug Safety, Informa Healthcare, 2008, 7 (2), pp.159-65. 〈10.1517/14740338.7.2.159〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00483415
Contributeur : Philippe Saas <>
Soumis le : vendredi 14 mai 2010 - 11:39:57
Dernière modification le : lundi 9 juillet 2018 - 13:12:02

Identifiants

Collections

Citation

Antoine Thiery-Vuillemin, Loic Chaigneau, Nadine Meaux-Ruault, Cristian Villanueva, Thierry N'Guyen, et al.. Anticancer therapy in patients with porphyrias: evidence today.. Expert Opinion on Drug Safety, Informa Healthcare, 2008, 7 (2), pp.159-65. 〈10.1517/14740338.7.2.159〉. 〈inserm-00483415〉

Partager

Métriques

Consultations de la notice

98